SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock and accompanying common warrants to purchase up to 15,000,000 shares of common stock. The shares of common st ...

SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common wa ...

Omnicom cross-agency collaboration to drive technology-led, innovative launch strategy Partnership brings together promising science, top-tier talent, and advanced technologies to enable a faster, smarter, and more effective path to address a critical public health need SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as ...

Smoking, the leading cause of preventable death and disease, continues to affect nearly 29 million adults in the U.S. alone If approved, cytisinicline will be the first new FDA-approved pharmacotherapy option for nicotine dependence in two decades More than 2,000 clinical trial participants contributed to the body of evidence submitted in the NDA demonstrating cytisinicline’s efficacy, safety, and tolerability profile SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life S ...

Achieve Life Sciences (ACHV) 2025 Conference June 04, 2025 05:30 PM ET Speaker0 Good evening, everyone, and welcome to the Jefferies Global Healthcare Conference. My name is Arjun with the Jefferies Investment Banking Team, and it is my great pleasure to introduce Richard Stewart, CEO of Achieve Life Sciences. Speaker1 Thank you very much and thank you for staying late today. It's my great pleasure to introduce you to Achieve Life Sciences and we're at a pivotal point in our development. We have several cat ...

Like millions of other investors, I got Robinhood and started trading during the pandemic. Unlike most of those investors, I carefully studied hundreds of earnings reports for clues to future performance, and I was able to identify many future winners, such as OPRX, OTRK, FUBO, and PLUG. My style of investing is identifying key information from earnings transcripts and reports that signify growth.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned ...

SEATTLE and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that the company will present at the Jefferies Global Healthcare Conference being held June 3–5, 2025, in New York City. Rick Stewart, Chief Executive Officer of Achieve, will present on Wednesday, ...

Oral Presentation to Highlight Key Benefits of Cytisinicline’s Dual Mechanism of Action to Pulmonary SpecialistsSEATTLE and VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that additional analyses from its Phase 3 ORCA-3 study will be presented during an oral ...

Achieve Life Sciences (ACHV) Q1 2025 Earnings Call May 13, 2025 08:30 AM ET Company Participants Nicole Jones - Investor RelationsRichard Stewart - CEO & DirectorCindy Jacobs - President, Chief Medical Officer & DirectorMark Oki - CFOGary Nachman - Managing Director - Equity ResearchJaime Xinos - Chief Commercial Officer Conference Call Participants Justin Walsh - Director & Research AnalystJohn Vandermosten - Senior Analyst Operator Greetings. Welcome to Achieve Life Sciences First Quarter twenty twenty fi ...

Achieve Life Sciences (ACHV) Q1 2025 Earnings Call May 13, 2025 08:30 AM ET Company Participants Nicole Jones - Investor RelationsRichard Stewart - CEO & DirectorCindy Jacobs - President, Chief Medical Officer & DirectorMark Oki - CFOGary Nachman - Managing Director - Equity ResearchJaime Xinos - Chief Commercial Officer Conference Call Participants Justin Walsh - Director & Research AnalystJohn Vandermosten - Senior Analyst Operator Greetings. Welcome to Achieve Life Sciences First Quarter twenty twenty fi ...